Skip to main content
Autobound logo
Merck10-K: Joint venture

Merck partners with Eisai Co., Ltd. on strategic oncology drug Lenvima.

Read at SEC EDGAR

What happened

Merck's collaboration with Eisai is crucial for its oncology franchise, a key growth area for the company. The complexity of co-developing and co-commercializing assets creates needs for integrated project management, financial tracking, and secure data exchange platforms.

Source

SEC EDGARFeb 24, 2026

Annual report (Form 10-K)

Merck 10-K for FY2025

Filing excerpt

Part of a global strategic oncology collaboration with Eisai Co., Ltd.

sec.gov/Archives/edgar/data/310158/000031015826000063/mrk-20251231.htmRead the full source

Other signals in this filing (8)

Extracted by Autobound

From the Signal API record
Signal
10-K: Joint venture

What this signalsFilings often name leadership changes, deals and spending plans.

Period
FY2025
Fiscal year end
12/31
Filed
Feb 24, 2026

More from Merck

Company page →

More 10-K signals at other companies

The full record

From the Signal API record

Details

CIK
310158
Accession number
0000310158-26-000063
Timeframe
Current year
Filing year
2026
Why it matters
New entity needs
Signal category
Strategic

Topics and mentions

Competitors

  • Eisai Co.
  • Ltd.

Competitors named

  • Eisai Co., Ltd.

Extraction

Confidence
High
Relevance
80%
Sentiment
Positive
Detected
Mar 3, 2026
signal_type
sec-10k
signal_subtype
jointVenture

Use this data

Get every 10-K signal for Merck and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Merck this week?”

    MCP setup guide

  2. Send it to your own tools

    The Signal API returns 10-K signals for any list of companies as JSON, for your CRM, warehouse or app.

    Signal API

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full sec-10k record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Start Free1,000 free creditsUse it in Claude via MCP
Show the full JSONThe record on this page and the API request

GET /v1/signals/af2f9e86-e550-4a07-92fd-b1f550948e49 returns this record as JSON. POST /v1/companies/enrich returns every signal for merck.com.

{
  "signal_id": "af2f9e86-e550-4a07-92fd-b1f550948e49",
  "signal_type": "sec-10k",
  "signal_subtype": "jointVenture",
  "detected_at": "2026-03-03T05:49:01.153+00:00",
  "company": {
    "name": "Merck",
    "domain": "merck.com"
  },
  "data": {
    "detail": "Merck's collaboration with Eisai is crucial for its oncology franchise, a key growth area for the company. The complexity of co-developing and co-commercializing assets creates needs for integrated project management, financial tracking, and secure data exchange platforms.",
    "metrics": {
      "timeframe": "current_year"
    },
    "summary": "Merck partners with Eisai Co., Ltd. on strategic oncology drug Lenvima.",
    "excerpts": "Part of a global strategic oncology collaboration with Eisai Co., Ltd.",
    "relevance": 0.8,
    "sentiment": "positive",
    "confidence": "high",
    "source_url": "https://www.sec.gov/Archives/edgar/data/310158/000031015826000063/mrk-20251231.htm",
    "filing_date": "2026-02-24",
    "filing_year": 2026,
    "fiscal_year_end": "12/31",
    "sales_relevance": "New entity needs",
    "signal_category": "strategic",
    "competitors_mentioned": [
      "Eisai Co., Ltd."
    ]
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.